SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase...
Read More Details
Finally We wish PressBee provided you with enough information of ( Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer )
Also on site :
- NYT Mini Crossword Answers, Hints for Friday, June 27, 2025
- Halle Berry Literally Bares It All in Carefree Bikini Dancing Video: 'Spectacular at 58'
- NYT 'Connections' Hint and Answers Today, Friday, June 27